Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-alpha, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis
- Authors
- Kim, Jung-Wook; Kim, Hyo Jong; Lee, Chang Kyun; Shim, Jae-Jun; Jang, Jae Young; Dong, Suk Ho; Kim, Byung-Ho; Chang, Young Woon; Chi, Sung-Gil
- Issue Date
- 12월-2014
- Publisher
- SPRINGER
- Keywords
- Immunohistochemistry; Infliximab; PRKCDBP; Tumor necrosis factor-alpha; Ulcerative colitis
- Citation
- DIGESTIVE DISEASES AND SCIENCES, v.59, no.12, pp.2947 - 2957
- Indexed
- SCIE
SCOPUS
- Journal Title
- DIGESTIVE DISEASES AND SCIENCES
- Volume
- 59
- Number
- 12
- Start Page
- 2947
- End Page
- 2957
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/96642
- DOI
- 10.1007/s10620-014-3282-4
- ISSN
- 0163-2116
- Abstract
- Background Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers. Recently, PRKCDBP was identified to be activated by nuclear factor-kappa B in response to tumor necrosis factor (TNF)-alpha. Aims To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-alpha signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy. Methods In total, 31 IFX therapy-naive patients (13 females; median age, 41 years) with moderate-to-severe UC who had been scheduled for IFX treatment were included. Immunohistochemical analysis of TNF-alpha and PRKCDBP expression was performed in rectal biopsies. Results A significant correlation was observed in immunoreactivity between TNF-alpha and PRKCDBP. IFX therapy reduced immunohistochemical expression of PRKCDBP and TNF-alpha (P < 0.001 and P = 0.005, respectively). The mean PRKCDBP expression level decreased from 54.5 to 30.2 %, and that of TNF-alpha decreased from 54.5 to 36.2 %. The immunohistochemical expression pre- and post-PRKCDBP therapy correlated significantly with TNF-alpha levels pre- and post-therapy (Spearman's rank correlation test; P = 0.005 and P = 0.001, respectively). Conclusions These results demonstrate that mucosal expression of PRKCDBP correlated strongly with TNF-alpha expression in UC patients and that IFX therapy resulted in profound reductions in both PRKCDBP and TNF-alpha. Thus, these findings support that PRKCDBP expression is tightly controlled by TNF-alpha, and the anti-inflammatory effect of IFX may in part stem from blockade of the TNF-alpha PRKCDBP signaling pathway.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Life Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.